<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495972</url>
  </required_header>
  <id_info>
    <org_study_id>DM Prevent POC</org_study_id>
    <nct_id>NCT04495972</nct_id>
  </id_info>
  <brief_title>Intestinimonas for Prevention of Type 2 Diabetes Mellitus</brief_title>
  <official_title>Novel Intestinal Microbiota-based Product for Preventing Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caelus Pharmaceuticals BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caelus Pharmaceuticals BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the effects of a microbiota-based product containing Intestinimonas&#xD;
      in adults with pre-diabetes. The purpose is to determine the safety and efficacy of the&#xD;
      microbiota-based product on insulin sensitivity in a target group of prediabetic individuals.&#xD;
      In particular, the objective is to evaluate whether Intestinimonas is able to improve the&#xD;
      insulin sensitivity, the response to the oral glucose tolerance test (OGTT) and whether it is&#xD;
      able to modulate the microbiota composition in the study subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to assess the effects of a microbiota-based product containing Intestinimonas&#xD;
      in adults with pre-diabetes.&#xD;
&#xD;
      Intestinimonas is an aerobic microorganism which produces butyrate and interacts with the&#xD;
      local microbiota in small and large intestine.&#xD;
&#xD;
      In preclinical studies, it was demonstrated that the insulin sensitivity can be enhanced by&#xD;
      Intestinimonas and similar microbiota.&#xD;
&#xD;
      The purpose is to determine the safety and efficacy of the microbiota-based product on&#xD;
      insulin sensitivity in a target group of prediabetic individuals.&#xD;
&#xD;
      The study participants will be subjects who are overweight and are at risk of developing Type&#xD;
      2 diabetes.&#xD;
&#xD;
      The key objective of this randomized, placebo-controlled study is to evaluate whether&#xD;
      Intestinimonas is able to improve the insulin sensitivity, to assess the response to the oral&#xD;
      glucose tolerance test (OGTT) and whether it is able to modulate the microbiota composition&#xD;
      in the study subjects.&#xD;
&#xD;
      Furthermore, in a open-label follow-up of 14 weeks the effect of a high-dose of&#xD;
      Intestinimonas will be compared with the low-dose tested in the initial double-blind&#xD;
      Randomised Controlled Trial (RCT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>12 weeks</time_frame>
    <description>as measured by Homeostatic Model Assessment (HOMA) - index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>as measured by Glucose in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of 2-hour blood glucose Area Under the Curve (AUC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>as measured by standard Oral Glucose Tolerance Test (OGTT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Experimental arm: Intestinimonas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intestinimonas in capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intestinimonas-capsules</intervention_name>
    <description>Capsules containing microbiota (Intestinimonas)</description>
    <arm_group_label>Experimental arm: Intestinimonas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-capsules</intervention_name>
    <description>Placebo capsules are identical to the active treatment</description>
    <arm_group_label>Placebo arm: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  increased BMI &gt; 25,&#xD;
&#xD;
          -  Fasting Plasma Glucose (FPG) 100-125 mg/dl or glucose &gt; 140 after OGTT, or HbA1c 5.7%&#xD;
             - 6.4%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luc Sterkman, MD</last_name>
    <phone>+31622979249</phone>
    <email>l.sterkman@caelushealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Piemonte Orientale</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Prodam, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetic State</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

